Clinical Trial Update: Oral Liquid 13-cis-retinoic Acid (13-CRA) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of oral liquid 13-cis-retinoic acid (13-CRA) in neuroblastoma has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Oral liquid 13-cis-retinoic acid (13-CRA) (13-cis-retinoic acid)

Snippet

Sponsor: Nova Laboratories Limited | Conditions: Neuroblastoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-10-19